Poster
103
(#103) Clinician Perspectives on Long-Acting Injectable Olanzapine Treatment Barriers and Unmet Needs From the SONAR (Survey on Olanzapine Needs and Attitudes Research) Study
Psych Congress 2025
Abstract: Olanzapine is an effective, commonly used, first-line treatment for schizophrenia. However, intramuscular (IM) long-acting injectable (LAI) olanzapine pamoate use in clinical practice is limited, due to the Risk Evaluation and Mitigation Strategy (REMS) requirements associated with post-injection delirium/sedation syndrome (PDSS). This analysis of the SONAR study aimed to assess US psychiatric clinician perceptions on treatment barriers and unmet needs associated with the current LAI olanzapine.
Surveys were sent via direct email (October-December 2024). Survey responses from 437 psychiatric clinicians (334 psychiatrists, 74 nurse practitioners/physician assistants, 29 psychiatry nurses) managing ≥1 patient with schizophrenia per month were evaluated.
Clinicians preferred using an LAI of the same antipsychotic when transitioning patients from oral to LAI formulations; 43% of clinicians preferred using IM LAI olanzapine pamoate when transitioning patients from oral olanzapine. However, only 29% were registered with the REMS program.
Clinicians reported staffing requirements (47%), time monitoring patients (46%), and need for emergency services (42%) associated with the REMS as the most impactful barriers to IM LAI olanzapine pamoate utilization; 58% were concerned about PDSS risk.
Most clinicians (76%) reported they would be more likely to use an LAI olanzapine without PDSS risk. Clinicians felt that an LAI olanzapine without the risk of PDSS would improve their overall management of patients with schizophrenia (72%) and increase oral olanzapine use (60%).
This survey highlights the access/management issues associated with REMS and underscores the strong clinician interest in an LAI olanzapine that is designed to eliminate the risk of PDSS.
Short Description: In this study, the primary barriers to clinical use of intramuscular long-acting injectable (LAI) olanzapine pamoate were related to the Risk Evaluation and Mitigation Strategy (REMS) requirements associated with post-injection delirium/sedation syndrome (PDSS), such as staffing, monitoring, and need for emergency services. Most clinicians (76%) reported they would be more likely to use an LAI olanzapine without the risk of PDSS, supporting the known clinician perception of olanzapine as an efficacious molecule for schizophrenia treatment.
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
Surveys were sent via direct email (October-December 2024). Survey responses from 437 psychiatric clinicians (334 psychiatrists, 74 nurse practitioners/physician assistants, 29 psychiatry nurses) managing ≥1 patient with schizophrenia per month were evaluated.
Clinicians preferred using an LAI of the same antipsychotic when transitioning patients from oral to LAI formulations; 43% of clinicians preferred using IM LAI olanzapine pamoate when transitioning patients from oral olanzapine. However, only 29% were registered with the REMS program.
Clinicians reported staffing requirements (47%), time monitoring patients (46%), and need for emergency services (42%) associated with the REMS as the most impactful barriers to IM LAI olanzapine pamoate utilization; 58% were concerned about PDSS risk.
Most clinicians (76%) reported they would be more likely to use an LAI olanzapine without PDSS risk. Clinicians felt that an LAI olanzapine without the risk of PDSS would improve their overall management of patients with schizophrenia (72%) and increase oral olanzapine use (60%).
This survey highlights the access/management issues associated with REMS and underscores the strong clinician interest in an LAI olanzapine that is designed to eliminate the risk of PDSS.
Short Description: In this study, the primary barriers to clinical use of intramuscular long-acting injectable (LAI) olanzapine pamoate were related to the Risk Evaluation and Mitigation Strategy (REMS) requirements associated with post-injection delirium/sedation syndrome (PDSS), such as staffing, monitoring, and need for emergency services. Most clinicians (76%) reported they would be more likely to use an LAI olanzapine without the risk of PDSS, supporting the known clinician perception of olanzapine as an efficacious molecule for schizophrenia treatment.
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
